SGLT2i in chronic kidney disease

in proteinuric CKD (min eGFR 25-30) w/ or w/o DM, transient ↓ in eGFR (<5) but then 30-40% ↓ risk of CKD progression & ↓ mortality (NEJM 2019;380:2295 & 2020;383:1436)